BERLIN, Oct 16 Reuters Shares in Germany39;s BioNTech fell on Monday after it flagged writedowns of up to 900 million euros 947 million reflecting similar charges its partner Pfizer announced on their COVID19 vaccine business last week.

Hit by a plunge in use of pandemicrelated products, Pfizer on Friday said it would take 900 million in writeoffs and other charges for their jointly developed Comirnaty vaccine, on top of much larger writeoffs on Pfizer39;s own COVID treatment Paxlovid.

For its thirdquarter accounts, BioNTech will likely recognise the effect of Pfizer39;s inventory writeoffs and other charges related to Comirnaty in the third quarter of 2023 up to 0.9 billion euros, which represents BioNTech39;s half of the gross profitsharing agreement with Pfizer, it said in a statement.

Shares in the vaccine maker, which is also developing cancer treatments, were down 7 to a twomonth low in Frankfurt as of 0756 GMT.

BioNTech, which relies on vaccinerelated profitsharing payments from its U.S. partner for much of its revenue, said the writeoffs would also reduce its 2023 revenue.

A BioNTech spokesperson on Monday declined to comment on the company39;s current 2023 outlook, which is for COVID19 vaccine revenue of about 5 billion euros.

The company is scheduled to release detailed thirdquarter figures on Nov. 6.

The company added that it had been told by Pfizer that most of the writeoffs relate to raw materials, as well as to inventories of vaccine versions that are…